A Phase 4 interventional study of metformin placebo and linagliptin placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 90 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-11-25.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 2 that started in 2011, is one of 22 in phase 4, and was the 26th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 689 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 27th largest by enrollment of the 96 interventional ones that give a count, is one of 11 that started in 2011, is one of 9 in phase 4, and was the 58th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate the impact of the combination therapy of linagliptin and metformin at submaximal doses in reduction of Glycosylated haemoglobin (HbA1c) and metformin pre-specified gastro-intestinal (GI) side effects in treatment naive patients of with type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Pre-menopausal women (last menstruation less than 1 year prior to informed consent) who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients to receive linagliptin +metformin QD
Drug: metformin · Drug: linagliptin
patients to receive metformin BID
Drug: metformin placebo · Drug: linagliptin placebo · Drug: metformin
metformin placebo tablets 500mg
linagliptin placebo tablets 5mg
metformin tablets 500mg
metformin tablets 500 mg
linagliptin tablets 5mg
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment
Adjusted mean change in HbA1c from baseline at Week 14 was analysed using an ANCOVA model. The Model included treatment and continuous baseline HbA1c.
Time frame: Baseline and 14 weeks
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 7.0% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe gastrointestinal (GI) side effects of metformin, as assessed by the investigators during 14 weeks of treatment)
Time frame: 14 weeks
Occurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment
Proportion of patients who experienced at least one metformin pre-specified moderate or severe GI side effect during 14 weeks
Time frame: 14 weeks
Change From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.
Time frame: Baseline and 14 weeks
Metformin Pre-specified GI Symptom Intensity Score Assessed by Investigators During 14 Weeks of Treatment
Patients could experience multiple events, therefore, multiple answers were possible for each patient.
Time frame: 14 weeks
Metformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment
The intensity of the GI side effects was also assessed by the patients using VAS scaled from 0 to 10; higher scores indicate more severe events. Means are adjusted by treatment and continuous baseline HbA1c.
Time frame: 14 weeks
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 6.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Time frame: 14 weeks
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment)
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.5% after 14 weeks of treatment).
Time frame: 14 weeks
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment)
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.8% after 14 weeks of treatment).
Time frame: 14 weeks
Composite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Time frame: 14 weeks
Change From Baseline in Body Weight by Visit at Week 14
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline weight
Time frame: Baseline and 14 weeks
Composite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.8% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Time frame: 14 weeks
Change From Baseline in HbA1c Over Time
Means are adjusted by treatment and continuous baseline HbA1c
Time frame: Baseline, 2 weeks and 8 weeks
| Milestone | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Started | 344 | 345 |
| Completed | 330 | 331 |
| Not completed | 14 | 14 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Other | 2 | 4 |
Adjusted mean change in HbA1c from baseline at Week 14 was analysed using an ANCOVA model. The Model included treatment and continuous baseline HbA1c.
| percent | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment | -0.99 ± 0.05 | -0.98 ± 0.04 |
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 7.0% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe gastrointestinal (GI) side effects of metformin, as assessed by the investigators during 14 weeks of treatment)
| participants | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment | 119 | 148 |
Proportion of patients who experienced at least one metformin pre-specified moderate or severe GI side effect during 14 weeks
| participants | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Occurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment | 25 | 28 |
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.
| mg/dL | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment | -24.5 ± 1.5 | -26.6 ± 1.4 |
Patients could experience multiple events, therefore, multiple answers were possible for each patient.
| events | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Mild | 114 | 153 |
| Moderate | 37 | 65 |
| Severe | 6 | 1 |
The intensity of the GI side effects was also assessed by the patients using VAS scaled from 0 to 10; higher scores indicate more severe events. Means are adjusted by treatment and continuous baseline HbA1c.
| units on a scale | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Metformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment | 4.9 ± 0.2 | 4.4 ± 0.2 |
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 6.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
| participants | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators | 83 | 95 |
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.5% after 14 weeks of treatment).
| participants | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) | 211 | 257 |
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.8% after 14 weeks of treatment).
| participants | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) | 162 | 187 |
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
| participants | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Composite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks | 194 | 236 |
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline weight
| kg | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Change From Baseline in Body Weight by Visit at Week 14 | -0.44 ± 0.14 | -1.05 ± 0.13 |
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.8% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
| participants | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| Composite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks | 149 | 175 |
Means are adjusted by treatment and continuous baseline HbA1c
| percent | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| At week 2 | -0.28 ± 0.02 | -0.25 ± 0.02 |
| At week 8 | -0.84 ± 0.04 | -0.78 ± 0.04 |
Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lina 5mg + Met qd | — | 2/344 (0.6%) | 101/344 (29.4%) |
| Met Bid | — | 7/345 (2%) | 121/345 (35.1%) |
| Event | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| CellulitisInfections and infestations | 0/344 | 2/345 |
| Pancreatitis acuteGastrointestinal disorders | 1/344 | 0/345 |
| AppendicitisInfections and infestations | 1/344 | 0/345 |
| Abdominal painGastrointestinal disorders | 0/344 | 1/345 |
| Epiploic appendagitisGastrointestinal disorders | 0/344 | 1/345 |
| Biliary dilatationHepatobiliary disorders | 0/344 | 1/345 |
| Cholecystitis acuteHepatobiliary disorders | 0/344 | 1/345 |
| Acute tonsillitisInfections and infestations | 0/344 | 1/345 |
| Comminuted fractureInjury, poisoning and procedural complications | 0/344 | 1/345 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/344 | 1/345 |
| Event | Lina 5mg + Met qd | Met Bid |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 62/344 | 74/345 |
| Urinary tract infectionInfections and infestations | 17/344 | 34/345 |
| Abdominal painGastrointestinal disorders | 23/344 | 29/345 |
| NauseaGastrointestinal disorders | 23/344 | 24/345 |
Treated set (TS): all patients treated with at least 1 dose of randomised study medication
| Age, Continuous(years) | Lina 5mg + Met qd | Met Bid | Total |
|---|---|---|---|
| Mean | 53.1 ± 10.7 | 52.9 ± 10.7 | 53.0 ± 10.7 |
| Sex: Female, Male(Participants) | Lina 5mg + Met qd | Met Bid | Total |
|---|---|---|---|
| Female | 175 | 187 | 362 |
| Male | 169 | 158 | 327 |
The record gives a start of Nov 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin